Ruffena Capital helps Cambrooke Therapeutics Inc. to secure USD $6m in Series C funding.
Cambrooke Therapeutics Inc. (“Cambrooke”), a global therapeutic nutrition innovator, announced the closing of the Series C investment round, led by Seventure Partners (Paris, France) introduced by Ruffena Capital, investing out of its latest healthcare and nutrition focused vehicle. Other co-investors from both Europe and the United States including Cambrooke's existing investor Galen Partners (Stamford, Connecticut) helped complete the round alongside Ruffena's lead investor.
Cambrooke’s core Medical Food portfolio serves the needs of people with phenylketonuria (PKU). The Company’s proprietary Glytactin protein source represents the first significant advance in PKU nutrition since newborn screening for PKU started in the late 1960s. Cambrooke recently expanded its focus to include products for people with other inborn errors of protein metabolism and for people with intractable epilepsy using ketogenic diet therapy. The Company compliments this portfolio with the most complete range of low protein functional foods for inborn errors of metabolism and a growing range of ketogenic diet therapy appropriate functional foods.
ABOUT CAMBROOKE THERAPUTICS
Founded in 2000, Cambrooke is a private equity backed, Massachusetts based therapeutic nutrition company and global provider of medical nutrition products for patients with serious chronic unmet medical needs. The company works with physicians and researchers from around the world to develop, test and commercialise products that are today focused on inborn errors of metabolism and intractable epilepsy.
ABOUT RUFFENA CAPITAL
Established in 2013, Ruffena Capital has evolved to become a boutique private equity advisory business with its own investment platform - focused on raising true growth capital or alternative finance, typically in the £2-10m range for its clients. Ruffena’s investors are largely a private audience of experienced UK and international investors, funds, family offices and certain wealth managers, who prefer established, highly tangible opportunities that can demonstrate the ability to scale and generate returns. Ruffena secured or advised upon over £42m going into client projects over the 2016-17 financial year. In the current year this has risen significantly and Ruffena has also had two clients IPO and one full exit in 2017-18. Ruffena does take on some earlier stage projects, however they must emphatically demonstrate thorough planning; tangible commercial potential; and a workable investment proposition.